Tango Therapeutics (NASDAQ:TNGX) Now Covered by Piper Sandler

Equities researchers at Piper Sandler assumed coverage on shares of Tango Therapeutics (NASDAQ:TNGXGet Free Report) in a note issued to investors on Monday, Briefing.com reports. The brokerage set an “overweight” rating and a $18.00 price target on the stock. Piper Sandler’s price objective would suggest a potential upside of 45.04% from the stock’s previous close.

Separately, B. Riley assumed coverage on shares of Tango Therapeutics in a research note on Friday, December 8th. They issued a “buy” rating and a $16.00 target price for the company.

Get Our Latest Report on Tango Therapeutics

Tango Therapeutics Stock Up 2.1 %

TNGX opened at $12.41 on Monday. The stock has a market cap of $1.27 billion, a P/E ratio of -11.18 and a beta of 0.95. The business has a fifty day moving average of $10.57 and a 200 day moving average of $8.70. Tango Therapeutics has a 52-week low of $2.47 and a 52-week high of $13.03.

Insider Buying and Selling at Tango Therapeutics

In related news, CEO Barbara Weber sold 4,681 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $12.56, for a total value of $58,793.36. Following the transaction, the chief executive officer now owns 1,539,624 shares in the company, valued at approximately $19,337,677.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Tango Therapeutics news, CEO Barbara Weber sold 4,681 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $12.56, for a total transaction of $58,793.36. Following the sale, the chief executive officer now owns 1,539,624 shares in the company, valued at approximately $19,337,677.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Adam Crystal sold 4,288 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $12.56, for a total transaction of $53,857.28. Following the completion of the transaction, the insider now directly owns 123,561 shares of the company’s stock, valued at approximately $1,551,926.16. The disclosure for this sale can be found here. Insiders have sold a total of 12,231 shares of company stock worth $153,703 over the last ninety days. Corporate insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds have recently modified their holdings of TNGX. Royal Bank of Canada bought a new position in Tango Therapeutics during the first quarter worth $32,000. Two Sigma Securities LLC purchased a new stake in shares of Tango Therapeutics in the 2nd quarter valued at approximately $40,000. Renaissance Technologies LLC purchased a new stake in Tango Therapeutics in the 3rd quarter worth about $41,000. XTX Topco Ltd acquired a new stake in shares of Tango Therapeutics during the 1st quarter valued at $44,000. Finally, HRT Financial LP purchased a new position in Tango Therapeutics in the first quarter valued at about $45,000. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Featured Stories

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.